⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 4, 2024Open Access

Figure S4 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer

Sara G. Danielli Jakob Wurth Sarah Morice Samanta Kisele Didier Surdez Olivier Delattre Peter K. Bode Marco Wachtel Beat W. Schäfer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Combination of chemotherapy and AXL inhibitors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Danielli et al. (2024) studied this question.

synapsesocial.com/papers/68e664c0b6db6435875f1772 https://doi.org/10.1158/1535-7163.25965055

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer2024
2Figure S2 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer2024
3Supplementary Data from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer2024
4Supplementary Data from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer2024
5Figure S5 from Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer2024